Article info

Download PDFPDF
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma

Authors

  • N. Arora Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California and PubMed articlesGoogle scholar articles
  • D. Tewari Oregon Health Sciences University, Portland, Oregon PubMed articlesGoogle scholar articles
  • C. Cowan Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California and PubMed articlesGoogle scholar articles
  • B. Saffari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California and PubMed articlesGoogle scholar articles
  • B. J. Monk Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California and PubMed articlesGoogle scholar articles
  • R. A. Burger Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, California and PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to: Devansu Tewari, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health Sciences University, L466, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA. Email: dtewari1{at}gmail.com

Citation

Arora N, Tewari D, Cowan C, et al
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma

Publication history

  • First published February 1, 2008.
Online issue publication 
February 01, 2008

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.